Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maat PharmaFRA:4RD +2.07%27 Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus rates FRA:4RD with a GF Score™ of 27/100 and a GF Value™ of €10.64 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 149 Biotechnology companies, Maat Pharma ranks worse than 671140.27% on this metric.
As of today (2026-07-25), the Forward Annual Dividend Yield of Maat Pharma is 0.00%.
As of today (2026-07-25), the Trailing Annual Dividend Yield of Maat Pharma is 0.00%.
FRA:4RD's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.42 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Maat Pharma (FRA:4RD) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Maat Pharma Forward Dividend Yield % Related Terms
FRA:4RD vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Maat Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Maat Pharma's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Maat Pharma (FRA:4RD) has a Forward Dividend Yield % of 0.00% as of Jul. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Maat Pharma and its competitors. According to the industry distribution chart, Maat Pharma ranks #999999 out of 149 companies in the Biotechnology industry.
Is Maat Pharma's Forward Dividend Yield % too high?
Maat Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Maat Pharma ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Maat Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 1.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.42, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Maat Pharma and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maat Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (FRA:4RD) is currently considered Possible Value Trap. The stock's GF Value™ is €10.64, compared to a current price of €2.71 — trading 74.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Maat Pharma (FRA:4RD), the current Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (FRA:4RD) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.71 is trading 74.5% below its estimated GF Value™ of €10.64.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for FRA:4RD:
Forward Dividend Yield %: 0.00%
GF Value™: €10.64 vs. price of €2.71 (74.5% below fair value)
No single metric tells the full story. See the FRA:4RD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score
Get the complete analysis for FRA:4RD
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RD has been successfully added to your 
